Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

Giuseppe Badalamenti, Antonio Russo, Francesco Pantano, Massimo Aglietta, Andrea Napolitano, Mariella Spalato Ceruso, Bruno Vincenzi, Giovanni Grignani, Giuseppe Tonini, Daniele Santini, Daniele Santini

Risultato della ricerca: Article

11 Citazioni (Scopus)

Abstract

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
Lingua originaleEnglish
pagine (da-a)1-6
Numero di pagine6
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume118
Stato di pubblicazionePublished - 2017

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cita questo

Badalamenti, G., Russo, A., Pantano, F., Aglietta, M., Napolitano, A., Spalato Ceruso, M., Vincenzi, B., Grignani, G., Tonini, G., Santini, D., & Santini, D. (2017). Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 118, 1-6.